IRVING, Texas--(BUSINESS WIRE)--The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare®, caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).
